#USA #New York #BrainStorm #ALS #NurOwn

BrainStorm Cell Therapeutics Releases Q1 2026 Financial Results and Corporate Update

On May 15, 2026, BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), recognized as a pioneer in adult stem cell therapeutics for neurodegenerative illnesses, announced its financial standings for the first quarter ending March 31, 2026, alongside significant corporate insights.

Focus on ALS Treatment

Chaim Lebovits, the company’s President and CEO, emphasized the team’s commitment to advancing the critical Phase 3 ENDURANCE trial featuring NurOwn, a pioneering treatment for Amyotrophic Lateral Sclerosis (ALS). The preparation phase is well underway, with site activations and regulatory interactions making promising progress. The initiation of this trial is crucial as it aims to treat patients diagnosed at earlier disease stages, with the intent of demonstrating NurOwn’s effectiveness in addressing ALS, an affliction known for its limited therapeutic options.

Lebovits stated, "The ongoing efforts are pivotal in ensuring we complete NurOwn's development and bring it to those who need it the most, particularly in the ALS community."

NurOwn Phase 3b ENDURANCE Study

The Phase 3b ENDURANCE study of NurOwn is designed to involve around 200 participants from leading ALS treatment centers. It encompasses a two-part structure: the first part being a 24-week randomized, double-blind, placebo-controlled segment, followed by a 24-week open-label phase. This design seeks to provide comprehensive insights regarding long-term safety and the durability of treatment effects, with the ALSFRS-R scale serving as the primary efficacy endpoint. Completion of the first part is anticipated to enable a new Biologics License Application (BLA) for NurOwn.

More detailed trial information can be accessed under ClinicalTrials.gov ID NCT06973629.

Recent Corporate Developments

In a bid to bolster operational capacities, BrainStorm has successfully secured $2 million through two strategic private placement agreements initiated in February 2026. These agreements are instrumental in stabilizing the company's valuation while providing resources for the upcoming operational endeavors and preparations linked to the ENDURANCE trial. Additionally, on May 4, 2026, the company entered further private placements, generating additional funding aimed at enhancing working capital and supporting corporate activities.

Financial Overview for Q1 2026

As of March 31, 2026, BrainStorm reported approximately $0.2 million in cash and cash equivalents, a slight decrease from $0.3 million on December 31, 2025. During the first quarter of 2026, the company’s research and development costs were about $0.8 million, showing a significant drop compared to $1.3 million in the same quarter in 2025. Administrative expenses amounted to approximately $1.3 million, down from roughly $1.8 million year-on-year. The net loss for the quarter was approximately $2.1 million, which demonstrates an improvement from a loss of around $2.9 million in Q1 2025. The net loss per share for both 2026 and 2025 stands at $(0.19) and $(0.45), respectively.

Looking Ahead

BrainStorm Cell Therapeutics is not only evolving its existing pipeline but also expanding focus towards innovative approaches in regenerative medicine. Its NurOwn technology platform remains central to its mission, aiming to address critical needs in neurodegenerative disease management. The company is actively preparing to initiate the Phase 3b study, illustrating its dedication to relief for patients suffering from ALS and beyond.

For further information on BrainStorm and its pivotal initiatives, visit their official website at BrainStorm Cell Therapeutics.

Conclusion

With encouraging financial results and significant advancements in clinical trial preparations, BrainStorm Cell Therapeutics stands poised to make substantial contributions towards treatment solutions for neurodegenerative diseases, particularly ALS, as it moves forward in its corporate journey.